Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 2/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 17/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 17/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20293732 | 0.86 | LIPE (0.43) | LIPEPDCD1CD274 | |
| SCHEMBL31108218 | 0.82 | PDCD1 (0.50) | LIPEPDCD1CD274 | |
| SCHEMBL30836689 | 0.81 | PDCD1 (0.51) | LIPEPDCD1CD274 | |
| SCHEMBL31353887 | 0.80 | PDCD1 (0.56) | PDCD1CD274 | |
| SCHEMBL31354281 | 0.80 | PDCD1 (0.56) | PDCD1CD274 | |
| SCHEMBL31108277 | 0.78 | PDCD1 (0.68) | LIPEPDCD1CD274 | |
| SCHEMBL20321427 | 0.77 | PDCD1 (0.59) | PDCD1CD274 | |
| SCHEMBL30836769 | 0.77 | LIPE (0.50) | LIPEPDCD1CD274 | |
| SCHEMBL30836660 | 0.76 | LIPE (0.49) | LIPEPDCD1CD274 | |
| SCHEMBL20293733 | 0.75 | PDCD1 (0.66) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11465981-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3558973-B1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-3558973-B1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20200325115-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-10-15 | — | — | US | disclosed |
| US-20200325115-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-10-15 | — | — | US | disclosed |
| EP-3558973-A1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180179179-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119221-A1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180179179-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119221-A1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325115-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | LIPE 3447/4885PDCD1 157/4885CD274 88/4885 |
| US-11465981-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | LIPE 3447/4885PDCD1 157/4885CD274 88/4885 |
| US-20180179179-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | LIPE 3447/4885PDCD1 157/4885CD274 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.